Unaudited Interim Results RUA Life Sciences plc (AIM: RUA), the holding company of a group of medical device businesses focused on the exploitation of Elast-Eon™, a long-term implantable biostable polymer , announces its unaudited interim results for the six months ended 30 September 2020. Highlights · Products on schedule for regulatory submission in 2021 · Positive testing on polymeric heart valve · The Group s cash continues to be well managed with cash at 30 September 2020 of £1,009,000 (31 March 2020: £1,976,000) and £1,440,000 at 30 November 2020 Bill Brown, Executive Chairman of RUA Life Sciences, said: A huge amount has been achieved by the team at RUA over the period and the business is now poised to successfully commercialise the vascular grafts and further develop our pioneering work in polymeric heart valves
Directorate Change RUA Life Sciences plc (AIM:RUA), the holding company of a group of medical device businesses focused on the exploitation of Elast-Eon™, a long-term implantable biostable polymer, announces that Gordon Wright has resigned as a non-executive Director of the Company with effect from 10 December 2020. As previously reported in the Company s audited results for the year ended 31 March 2020, Gordon, who was the founder of the predecessor AorTech business, has decided to retire from the Board now that the business has been re-established with an exciting future ahead of it. The Directors wish to thank Gordon for his support and guidance over the years and look forward to working with him in his new role as Honorary Life President.